CY1122452T1 - Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων - Google Patents

Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων

Info

Publication number
CY1122452T1
CY1122452T1 CY20191100928T CY191100928T CY1122452T1 CY 1122452 T1 CY1122452 T1 CY 1122452T1 CY 20191100928 T CY20191100928 T CY 20191100928T CY 191100928 T CY191100928 T CY 191100928T CY 1122452 T1 CY1122452 T1 CY 1122452T1
Authority
CY
Cyprus
Prior art keywords
oligosaccharites
conjugations
amino acid
acid group
group
Prior art date
Application number
CY20191100928T
Other languages
English (en)
Inventor
Yunxiang Zhu
Seng H. Cheng
Canwen Jiang
Luis Z. Avila
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of CY1122452T1 publication Critical patent/CY1122452T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Η εφεύρεση παρέχει μεθόδους για τη σύνθεση ολιγοσακχαριτών που περιλαμβάνουν ομάδα αμινοοξυ-. Η εφεύρεση παρέχει περαιτέρω ολιγοσακχαρίτες που περιλαμβάνουν μια ομάδα αμινοοξυ-, μεθόδους για σύζευξη ολιγοσακχαριτών που περιλαμβάνουν μια ομάδα αμινοοξυ- σε γλυκοπρωτεΐνες και συζεύγματα ολιγοσακχαρίτη-πρωτεΐνης. Παρέχονται, επίσης, μέθοδοι θεραπείας μιας διαταραχής λυσοσωμικής αποθήκευσης, σε ένα θηλαστικό, με τη χορήγηση ενός συζεύγματος ολιγοσακχαρίτη-πρωτεΐνης.
CY20191100928T 2007-01-18 2019-09-04 Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων CY1122452T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88547107P 2007-01-18 2007-01-18
PCT/US2008/051429 WO2008089403A2 (en) 2007-01-18 2008-01-18 Oligosaccharides comprising an aminooxy group and conjugates thereof
EP08727910.5A EP2121713B1 (en) 2007-01-18 2008-01-18 Oligosaccharides comprising an aminooxy group and conjugates thereof

Publications (1)

Publication Number Publication Date
CY1122452T1 true CY1122452T1 (el) 2021-01-27

Family

ID=39473250

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100094T CY1119954T1 (el) 2007-01-18 2018-01-24 Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων
CY20191100928T CY1122452T1 (el) 2007-01-18 2019-09-04 Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100094T CY1119954T1 (el) 2007-01-18 2018-01-24 Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων

Country Status (19)

Country Link
US (5) US8759501B2 (el)
EP (5) EP2457920B1 (el)
JP (6) JP5999867B2 (el)
CN (2) CN101631794B (el)
CA (1) CA2675968C (el)
CY (2) CY1119954T1 (el)
DK (3) DK2457920T3 (el)
ES (3) ES2656314T3 (el)
FR (1) FR22C1061I2 (el)
HR (3) HRP20130744T1 (el)
HU (3) HUE036140T2 (el)
IL (3) IL243117B2 (el)
LT (2) LT2457919T (el)
NL (1) NL301210I2 (el)
NO (2) NO2457920T3 (el)
PL (3) PL2457920T3 (el)
PT (3) PT2457919T (el)
SI (2) SI2457920T1 (el)
WO (1) WO2008089403A2 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2008013735A2 (en) * 2006-07-21 2008-01-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
NO2457920T3 (el) * 2007-01-18 2018-03-24
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
BRPI0923047B8 (pt) 2008-12-16 2021-05-25 Genzyme Corp métodos para preparação de conjugados de proteínas- oligossacarídeos
US8962573B2 (en) 2009-07-03 2015-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
CA2769244A1 (en) * 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
NZ623810A (en) * 2009-07-27 2015-10-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011163572A2 (en) 2010-06-24 2011-12-29 University Of Kansas Bifunctional conjugate compositions and associated methods
WO2012082635A1 (en) * 2010-12-13 2012-06-21 Ancora Pharmaceuticals, Inc. Synthetic oligosaccharide group a streptococcus
WO2012098537A1 (en) 2011-01-20 2012-07-26 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
CN105189542A (zh) 2013-02-20 2015-12-23 瓦莱里昂治疗有限责任公司 用于治疗庞贝氏症的方法和组合物
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
TWI821227B (zh) 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記
MX2021005245A (es) * 2018-11-08 2021-06-18 Kaleido Biosciences Inc Composiciones de oligosacaridos y metodos de uso de las mismas.
US20230398224A1 (en) 2020-02-07 2023-12-14 Novartis Ag Targeted plasma protein degradation
CN115715218A (zh) 2020-02-08 2023-02-24 建新公司 治疗庞贝病的组合物和方法
MX2022016019A (es) 2020-06-14 2023-04-10 Genzyme Corp Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio.

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
DE2940845B1 (de) 1979-10-09 1980-06-26 Ford Werke Ag Kreiselpumpendichtung,insbesondere fuer Kuehlwasserpumpen in Kraftfahrzeugen
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
IL93432A (en) 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5212298A (en) * 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5324663A (en) * 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5583042A (en) * 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5492821A (en) * 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
WO1992016212A1 (en) * 1991-03-13 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
CA2101918A1 (en) 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
FR2721612B1 (fr) * 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPO190596A0 (en) * 1996-08-26 1996-09-19 Alchemia Pty Ltd Oligosaccharide synthesis
JP4290766B2 (ja) * 1997-01-21 2009-07-08 サノフィ・パスツール 多糖―ペプチド複合体
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
US6538117B1 (en) * 1999-08-10 2003-03-25 The Scripps Research Institute Programmable one-pot oligosaccharide synthesis
JP2004505885A (ja) * 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
US6399575B1 (en) * 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
AU779887B2 (en) * 1999-06-08 2005-02-17 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
US6770468B1 (en) * 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6537785B1 (en) * 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
WO2001060412A2 (en) 2000-02-15 2001-08-23 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6749865B2 (en) * 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US20040067527A1 (en) 2000-07-26 2004-04-08 Sara Lavi Intracellular delivery system for protein phosphatases and other polypeptides
JP2004507467A (ja) * 2000-08-18 2004-03-11 マサチューセッツ　インスティテュート　オブ　テクノロジー オリゴ糖の自動化合成のための装置及び方法
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
DE60224816T2 (de) * 2001-04-30 2009-01-22 ZyStor Therapeutics, Inc., Milwaukee Subzelluläres targeting von therapeutischen proteinen
WO2001090139A2 (en) 2001-05-07 2001-11-29 Supratek Pharma Inc. A ligand for enhancing oral and cns delivery of biological agents
BR122015016313B8 (pt) 2001-07-16 2021-05-25 Genzyme Corp composto semelhante à ceramida e método de preparar um composto
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
TWI295483B (en) 2002-01-31 2008-04-01 Sumitomo Chemical Co 3-5 group compound semiconductor, process for producing the same, and compound semiconductor element using the same
EP1585817B1 (en) * 2002-02-20 2009-09-02 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
DE02020425T1 (de) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
WO2004024776A1 (en) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005002515A2 (en) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
RU2327703C2 (ru) 2003-08-12 2008-06-27 Лайпоксен Текнолоджиз Лимитед Производные полисиаловой кислоты
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
US7176185B2 (en) * 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
CA2556169C (en) * 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
SI1740204T1 (en) 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. MEDICAL APPLICATION OF ALFA-MANOSIDES
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US7341720B2 (en) 2005-04-06 2008-03-11 Genzyme Corporation Targeting of glycoprotein therapeutics
NO2457920T3 (el) 2007-01-18 2018-03-24
WO2008089339A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
BRPI0923047B8 (pt) * 2008-12-16 2021-05-25 Genzyme Corp métodos para preparação de conjugados de proteínas- oligossacarídeos

Also Published As

Publication number Publication date
EP3597655B1 (en) 2023-08-02
IL199925A0 (en) 2010-04-15
CA2675968C (en) 2019-05-21
JP2020185011A (ja) 2020-11-19
DK2121713T3 (da) 2013-06-24
ES2656314T3 (es) 2018-02-26
CN102978185B (zh) 2015-02-11
US20170014520A1 (en) 2017-01-19
CN101631794B (zh) 2013-01-02
PL2121713T3 (pl) 2013-11-29
PL2457920T3 (pl) 2018-03-30
JP5999867B2 (ja) 2016-09-28
HRP20180076T1 (hr) 2018-02-23
US10907142B2 (en) 2021-02-02
CN101631794A (zh) 2010-01-20
ES2744574T3 (es) 2020-02-25
JP6039625B2 (ja) 2016-12-07
US20200010825A1 (en) 2020-01-09
HUE036140T2 (hu) 2018-06-28
EP2457920B1 (en) 2017-10-25
HRP20130744T1 (hr) 2013-10-11
PL2457919T3 (pl) 2019-12-31
CY1119954T1 (el) 2018-12-12
US8759501B2 (en) 2014-06-24
WO2008089403A3 (en) 2008-11-13
EP2121713A2 (en) 2009-11-25
EP4293112A3 (en) 2024-03-13
PT2457919T (pt) 2019-09-20
NL301210I2 (nl) 2023-02-02
JP2018109194A (ja) 2018-07-12
CA2675968A1 (en) 2008-07-24
IL243117B (en) 2022-11-01
IL199925A (en) 2017-09-28
EP2457919A1 (en) 2012-05-30
NO2022056I1 (no) 2022-12-09
HUS2200055I1 (hu) 2023-01-28
PT2121713E (pt) 2013-06-25
WO2008089403A2 (en) 2008-07-24
EP2457919B1 (en) 2019-06-05
ES2417146T3 (es) 2013-08-06
FR22C1061I2 (fr) 2023-11-17
NO2457920T3 (el) 2018-03-24
JP6309592B2 (ja) 2018-04-11
IL243117B2 (en) 2023-03-01
HRP20191562T1 (hr) 2019-11-29
EP3597655A1 (en) 2020-01-22
PT2457920T (pt) 2018-01-23
US9469850B2 (en) 2016-10-18
SI2457919T1 (sl) 2019-10-30
SI2457920T1 (en) 2018-02-28
EP4293112A2 (en) 2023-12-20
DK2457919T3 (da) 2019-09-16
JP2010516257A (ja) 2010-05-20
FR22C1061I1 (fr) 2023-02-03
US20150050262A1 (en) 2015-02-19
JP2015078360A (ja) 2015-04-23
LT2457920T (lt) 2018-02-12
LT2457919T (lt) 2019-09-25
EP2121713B1 (en) 2013-06-12
JP2017052962A (ja) 2017-03-16
US20220204963A1 (en) 2022-06-30
HUE045046T2 (hu) 2019-12-30
IL243117A (el) 2016-01-31
EP2457920A1 (en) 2012-05-30
NL301210I1 (nl) 2022-12-21
CN102978185A (zh) 2013-03-20
JP2022137232A (ja) 2022-09-21
DK2457920T3 (en) 2018-01-22
US20100047225A1 (en) 2010-02-25
IL222792A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
CY1122452T1 (el) Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων
CY1121860T1 (el) Συνθετικα ενδιαμεσα για την παρασκευη συζευγματων ολιγοσακχαριτη-πρωτεϊνης
CY1123684T1 (el) Θεραπευτικες συνθεσεις νουκλεασης και μεθοδοι
UA111341C2 (uk) Аматоксиновий кон'югат з покращеними лінкерами
TR201900176T4 (tr) Anti-TROP2 antikor-ilaç konjugatı.
CY1119048T1 (el) Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
NZ754810A (en) Pyrrolobenzodiazepine-antibody conjugates
UA108598C2 (xx) Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
PH12015501422B1 (en) Hydrophilic self-immolative linkers and conjugates thereof
CY1112278T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
EA201792652A3 (ru) Новые производные майтанзиноида с пептидным линкером и их конъюгаты
EA201001625A1 (ru) Человеческие сывороточные альбуминовые линкеры и их конъюгаты
CY1121943T1 (el) Πυρηνοφιλοι καταλυτες για συνδεση οξιμων
EA201390940A1 (ru) Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком
EA201070463A1 (ru) Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство
EP2952210A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
EA028186B9 (ru) Способ конъюгации водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок
CY1116782T1 (el) Χρηση s-αδενοσυλμεθειονινης (sam) και υπεροξειδικης δισμουτασης (sod) για την παρασκευη φαρμακων για την αγωγη της νοσου toy alzheimer
CY1114320T1 (el) Ολιγοσακχαριτες που περιλαμβανουν αμινοοξυ-ομαδα και συζευγματα αυτων
EA202092369A1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака
CY1124642T1 (el) Εξανθρωπισμος αντισωματων κονικλου χρησιμοποιωντας εναν καθολικο σκελετο αντισωματος
BRPI0917819B8 (pt) compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado
CY1116394T1 (el) Συζευγματα ολιγοσακχαριτη-πρωτεϊνης
CY1116022T1 (el) Μονοκλωνικα αντισωματα τα οποια δεσμευουν ton β7η6 και χρησεις αυτων